Inosine monophosphate dehydrogenase as a probe in antiviral drug discovery

Antiviral Chemistry and Chemotherapy

Volumn 18, Issue 5, 2007, Pages 245-258

  Nair, Vasu ^a   Shu, Qingning ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Antiviral agents; IMPDH; Inhibitor

Indexed keywords

2 (FLUOROVINYL)INOSINE MONOPHOSPHATE; 2 VINYLINOSINE MONOPHOSPHATE; 3 DEAZAGUANOSINE MONOPHOSPHATE; 5 ETHYNYL 1 BETA DEXTRO RIBOFURANOSYLIMIDAZOLE 4 CARBOXAMIDE; 6 CHLOROPURINE NUCLOESIDE MONOPHOSPHATE; BMS 337197; ENTECAVIR; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; MERIMEPODIB; MIZORIBINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PM 523; RIBAVIRIN; SELENAZOFURIN; TIAZOFURIN; UNCLASSIFIED DRUG; VX 148;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 36849021519     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020701800501     Document Type: Review

References (91)

1. Antonino LC, Straub K & Wu JC (1994) Probing the active site of human IMP dehydrogenase using halogenated purine riboside 5′-monophosphates and covalent modification reagents. Biochemistry 33:1760-1765.
2. Balzarini J, Karlsson A, Wang L, Bohman C, Horska K, Vbtruba I, Fridland A, Van Aerschot A, Herdewijn P & De Clercq E (1993) Eicar (5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. Journal of Biological Chemistry 268:24591-24598.
3. Balzarini J, Lee CK, Herdewijn P & De Clercq E (1991a) Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′- dideoxyinosine against human immunodeficiency virus. Journal of Biological Chemistry 266:21509-21514.
4. Balzarini J, Lee CK, Schols D & De Clercq E (1991b) 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethnyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2′,3′-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes. Biochemical and Biophysical Research Communications 178:563-569.
5. Balzarini J, Stet L, Matsuda A, Wiebe L, Knauss E & De Clercq E (1998) Metabolism of EICAR (5-ethynyl-1-β-D- ribofuranosylimidazole-4-carboxamide), a potent inhibitor of inosinate dehydrogenase. Advances in Experimental Medicine and Biology 431:723-728.
6. Bowne SJ, Sullivan LS, Blanton SH, Cepko CL, Blackshaw S, Birch DG, Hughbanks-Wheaton D, Heckenlively JR & Daiger SP (2002) Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Human Molecular Genetics 11:559-568.
7. Brox LW & Hampton A (1968) Inactivation of guanosine 5′-phosphate reductase by 6-chloro-, 6-mercapto-, and 2-amino-6-mercapto- 9-β-D-ribofuranosylpurine 5′-phosphates. Biochemistry 7:398-406.
8. Buckley GM, Davies N, Dyke HJ, Gilbert PJ, Hannah DR, Haughan AF, Hunt CA, Pitt WR, Profit RH, Ray NC, Richard MD, Sharpe A, Taylor AJ, Whitworth JM & Williams SC (2005) Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships. Bioorganic & Medicinal Chemistry Letters 15:751-754.
9. Chong CR, Qian DZ, Pan F, Wei Y, Pili R, Sullivan DJ Jr & Liu JO (2006) Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. Journal of Medicinal Chemistry 49:2677-2680.
10. Colby TD, Vanderveen K, Strickler MD, Markham GD & Goldstein BM (1999) Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proceedings of the National Academy of Sciences of the United States of America 96:3531-3536.
11. Cook PD, Rousseau RJ, Mian AM, Dea P, Meyer RB Jr & Robins RK (1976) Synthesis of 3-deazaguanine, 3-deazaguanosine, and 3-deazaguanylic acid by a novel ring closure of imidazole precursors. Journal of the American Chemical Society 98:1492-1498.
12. Cooney DA, Jayaram HN, Gebeyehu G, Betts CR, Kelley JA, Marquez VE & Johns DG (1982) The conversion of 2-β-D-ribofuranosylthiazole-4- carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochemical Pharmacology 31:2133-2136.
13. Cooper AC, Banasiak NC & Allen PJ (2003) Management and prevention strategies for respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a review of evidence-based practice interventions. Pediatric Nursing 29:452-456.
14. Crotty S, Cameron CE & Andino R (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proceedings of the National Academy of Sciences of the United States of America 98:6895-6900.
15. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R & Cameron CE (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Medicine 6:1375-1379.
16. Dayton JS, Lindsten T, Thompson CB & Mitchell BS (1994) Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. Journal of Immunology 152:984-991.
17. De Clercq E (2001) Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clinical Microbiology Reviews 14:382-397.
18. De Clercq E, Cools M, Balzarini J, Snoeck R, Andrei G, Hosoya M, Shigeta S, Ueda T, Minakawa N & Matsuda A (1991) Antiviral activities of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrobial Agents and Chemotherapy 35:679-684.
19. Dhar TGM, Shen Z, Guo J, Liu C, Watterson SH, Gu HH, Pitts WJ, Fleener CA, Rouleau KA, Sherbina NZ, McIntyre KW, Witmer MR, Tredup JA, Chen B-C, Zhao R, Bednarz MS, Cheney DL, MacMaster JF, Miller LM, Berry KK, Harper TW, Barrish JC, Hollenbaugh DL & Iwanowicz EJ (2002) Discovery of N-[2-[2-[[3- Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity. Journal of Medicinal Chemistry 45:2127-2130.
20. Digits JA & Hedstrom L (1999) Species-Specific Inhibition of Inosine 5′-monophosphate dehydrogenase by mycophenolic acid. Biochemistry 38:15388-15397.
21. + site of IMP dehydrogenase. Biochemistry 39:1771-1777.
22. Fleming MA, Chambers SP, Connelly PR, Nimmesgern E, Fox T, Bruzzese FJ, Hoe ST, Fulghum JR, Livingston DJ, Stuver CM, Sintchak MD, Wilson KP & Thomson JA (1996) Inhibition of IMPDH by mycophenolic acid: dissection of forward and reverse pathways using capillary electrophoresis. Biochemistry 35:6990-6997.
23. Franchetti P, Cappellacci L & Grifantini M (1996) IMP dehydrogenase as a target of antitumor and antiviral chemotherapy. Farmaco 51:457-469.
24. Franklin TJ, Jacobs V, Bruneau P & Ple P (1995) Glucuronidation by human colorectal adenocarcinoma cells as a mechanism of resistance to mycophenolic acid. Advances in Enzyme Regulation 35:91-100.
25. + orients the active site loop for catalysis. Biochemistry 41:13309-13317.
26. Gebeyehu G, Marquez VE, Van Cott A, Cooney DA, Kelley JA, Jayaram HN, Ahluwalia GS, Dion RL, Wilson YA & Johns DG (1985) Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogs. Synthesis, structure, and interactions with IMP dehydrogenase. Journal of Medicinal Chemistry 28:99-105.
27. Gharehbaghi K, Sreenath A, Hao Z, Pauli KD, Szekeres T, Cooney DA, Krohn K & Jayaram HN (1994) Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin. Biochemical Pharmacology 48:1413-1419.
28. Graci JD & Cameron CE (2006) Mechanisms of action of ribavirin against distinct viruses. Reviews in Medical Virology 16:37-48.
29. Gu JJ, Tolin AK, Jain J, Huang H, Santiago L & Mitchell BS (2003) Targeted disruption of the inosine 5′-monophosphate dehydrogenase type I gene in mice. Molecular and Cellular Biology 23:6702-6712.
30. Hager PW, Collart FR, Huberman E & Mitchell BS (1995) Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochemical Pharmacology 49:1323-1329.
31. Hedstrom L & Gan L (2006) IMP dehydrogenase: structural schizophrenia and an unusual base. Current Opinion in Chemical Biology 10:520-525.
32. Holland JJ, Domingo E, de la Torre JC & Steinhauer DA (1990) Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poHovirus can be increased only slightly by chemical mutagenesis. Journal of Virology 64:3960-3962.
33. Ichimura H & Levy JA (1995) Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 211:554-560.
34. Ishikawa H (1999) Mizoribine and mycophenolate mofetil. Current Medicinal Chemistry 6:575-597.
35. Jain J, Almquist SJ, Heiser AD, Shlyakhter D, Leon E, Memmott C, Moody CS, Nimmesgern E & Decker C (2002) Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5′- monophosphate dehydrogenase inhibitor. Journal of Pharmacology and Experimental Therapeutics 302:1272-1277.
36. Jashes M, Mlynarz G, De Clercq E & Sandino AM (2000) Inhibitory effects of EICAR on infectious pancreatic necrosis virus replication. Antiviral Research 45:9-17.
37. Jayaram HN, Ahluwalia GS, Dion RL, Gebeyehu G, Marquez VE, Kelley JA, Robins RK, Cooney DA & Johns DG (1983) Conversion of 2-β-D- ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochemical Pharmacology 32:2633-2636.
38. Jayaram HN, Gharehbaghi K, Jayaram NH, Rieser J, Krohn K & Paull KD (1992) Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells. Biochemical and Biophysical Research Communications 186:1600-1606.
39. Kato N, Naka K, Yano M, Abe K, Dansako H & Ikeda M (2006) Mizoribine: a new growth inhibitor for hepatitis C virus. Therapeutic Research 27:654-660.
40. Kerr KM & Hedstrom L (1997) The roles of conserved carboxylate residues in IMP dehydrogenase and identification of a transition state analog. Biochemistry 36:13365-13373.
41. Kirsi JJ, McKernan PA, Burns NJ, III, North JA, Murray BK & Robins RK (1984) Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin. Antimicrobial Agents and Chemotherapy 26:466-475.
42. Kirsi JJ, North JA, McKernan PA, Murray BK, Canonico PG, Huggins JW, Srivastava PC & Robins RK (1983) Broad-spectrum antiviral activity of 2-β-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrobial Agents and Chemotherapy 24:353-361.
43. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F & L Valantine H (1998) A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 66:507-515.
44. Konno Y, Natsumeda Y, Nagai M, Yamaji Y, Ohno S, Suzuki K & Weber G (1991) Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal lymphocytes and leukemic cell lines. Journal of Biological Chemistry 266:506-509.
45. Kosugi Y, Saito Y, Mori S, Watanabe J, Baba M & Shigeta S (1994) Antiviral activities of mizoribine and other inosine monophosphate dehydrogenase inhibitors against several ortho- and paramyxoviruses. Antiviral Chemistry & Chemotherapy 5:366-371.
46. Lee CH, Gilbertson DL, Novella IS, Huerta R, Domingo E & Holland JJ (1997) Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus. Journal of Virology 71:3636-3640.
47. Leyssen P, Balzarini J, De Clercq E & Neyts J (2005) The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. Journal of Virology 79:1943-1947.
48. Leyssen P, De Clercq E & Neyts J (2006) The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Molecular Pharmacology 69:1461-1467.
49. Link JO & Straub K (1996) Trapping of an IMP dehydrogenase-substrate covalent intermediate by mycophenolic acid. Journal of the American Chemical Society 118:2091-2092.
50. Markland W, McQuaid TJ, Jain J & Kwong AD (2000) Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrobial Agents and Chemotherapy 44:859-866.
51. Marquez VE, Tseng CKH, Gebeyehu G, Cooney DA, Ahluwalia GS, Kelley JA, Dalal M, Fuller RW, Wilson YA & Johns DG (1986) Thiazole-4-carboxamide adenine dinucleotide (TAD). Analogs stable to phosphodiesterase hydrolysis. Journal of Medicinal Chemistry 29:1726-1731.
52. Matsuda A, Minakawa N, Sasaki T & Ueda T (1988) The design, synthesis and antileukemic activity of 5-alkynyl-1-β-D- ribofuranosylimidazole-4-carboxamides. Chemical & Pharmaceutical Bulletin 36:2730-2733.
53. McHutchison JG, Shiffman ML, Cheung RC, Gordon SC, Wright TL, Pottage JC, Jr., McNair L, Ette E, Moseley S & Alam J (2005) A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-α in previously untreated patients with chronic hepatitis C. Antiviral Therapy 10:635-643.
54. Minakawa N & Matsuda A (1999) Mechanism-based design of inosine 5-monophosphate dehydrogenase inhibitors: synthesis and biological activities of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives. Current Medicinal Chemistry 6:615-628.
55. Minakawa N, Takeda T, Sasaki T, Matsuda A & Ueda T (1991) Nucleosides and nucleotides. 96. Synthesis and antitumor activity of 5-ethynyl-1-β- D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives. Journal of Medicinal Chemistry 34:778-786.
56. Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K, Asano K & Matsuda T (1974) Studies on bredinin. I. Isolation, characterization, and biological properties. Journal of Antibiotics 27:775-782.
57. Nagai M, Natsumeda Y, Konno Y, Hoffman R, Irino S & Weber G (1991) Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Research 51:3886-3890.
58. Nagai M, Natsumeda Y & Weber G (1992) Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Research 52:258-261.
59. Nair V, Ma X, Zhang F, Nishonov M, Shu Q, Sidwell RW, & Kern, ER (2007) New ribonucleosides with surrogate bases: synthesis, enzymology, molecular docking studies and antiviral activity, Antiviral Research 74:A74.
60. Nair V, Bonsu E, Gupta M, & Story S (2005) Discovery of antiviral agents against RNA viruses: correlation with inhibition of IMPDH Antiviral Research 65:A67.
61. Nair V (2005) IMPDH inhibitors. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats. Edited by PF Torrence. Hoboken, NJ: John Wiley & Sons; pp. 179-202.
62. Nair V, Bera B & Kern ER (2003) Synthesis and biological activities of 2-functionalized purine nucleosides. Nucleosides, Nucleotides & Nucleic Acids 22:115-127.
63. Nair V & Kamboj RC (2003) Inhibition of inosine monophosphate dehydrogenase (IMPDH) by 2-[2-(Z)-fluorovinyl]inosine 5′-monophosphate. Bioorganic & Medicinal Chemistry Letters 13:645-647.
64. Nair V & Ussery MA (1992) New hypoxanthine nucleosides with RNA antiviral activity. Antiviral Research 19:173-178.
65. Naka K, Ikeda M, Abe K-i, Dansako H & Kato N (2005) Mizoribine inhibits hepatitis C virus RNA replication: Effect of combination with interferon-α. Biochemical and Biophysical Research Communications 330:871-879.
66. Neyts J, Meerbach A, McKenna P & De Clercq E (1996) Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Research 30:125-132.
67. Pal S, Bera B & Nair V (2002) Inhibition of inosine monophosphate dehydrogenase (IMPDH) by the antiviral compound, 2-vinylinosine monophosphate. Bioorganic & Medicinal Chemistry 10:3615-3618.
68. Panattoni A, D'Anna F & Triolo E (2007) Antiviral activity of tiazofurin and mycophenolic acid against Grapevine Leafroll-associated Virus 3 in Vitis vinifera explants. Antiviral Research 73:206-211.
69. Pankiewicz KW & Goldstein BM (Editors) Inosine monophosphate dehydrogenase: a major therapeutic target. ACS Symposium Series 839; 2003
70. Pankiewicz KW, Patterson SE, Black PL, Jayaram HN, Risal D, Goldstein BM, Stuyver LJ & Schinazi RF (2004) Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IMPDH) - the major therapeutic target. Current Medicinal Chemistry 11:887-900.
71. Pawlotsky J-M (2003) Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Research 59:1-11.
72. Pickett SD, Sherborne BS, Wilkinson T, Bennett J, Borkakoti N, Broadhurst M, Hurst D, Kilford I, McKinnell M & Jones PS (2003) Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. Bioorganic & Medicinal Chemistry Letters 13:1691-1694.
73. Ratcliffe AJ (2006) Inosine 5′-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases. Current Opinion in Drug Discovery & Development 9:595-605.
74. Robertson CM, Hermann LL & Coombs KM (2004) Mycophenolic acid inhibits avian reovirus replication. Antiviral Research 64:55-61.
75. Robins RK, Revankar GR, McKernan PA, Murray BK, Kirsi JJ & North JA (1985) The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity of ribavirin and selenazofurin. Advances in Enzyme Regulation 24:29-43.
76. Shaw LM, Sollinger HW, Halloran P, Morris RE, Yatscoff RW, Ransom J, Tsina I, Keown P, Holt DW & Lieberman R (1995) Mycophenolate mofetil: a report of the consensus panel. Therapeutic Drug Monitoring 17:690-699.
77. Shigeta S, Mori S, Baba M, Ito M, Honzumi K, Nakamura K, Oshitani H, Numazaki Y, Matsuda A, Obara T, Shuto S & de Clercq E (1992) Antiviral activities of ribavirin, 5-ethynyl-1-β-D-ribofuranosylimidazole-4- carboxamide, and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrobial Agents and Chemotherapy 36:435-439.
78. Shigeta S, Mori S, Watanabe J, Soeda S, Takahashi K & Yamase T (1997) Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo. Antimicrobial Agents and Chemotherapy 41:1423-1427.
79. Shiraki K, Ishibashi M, Okuno T, Kokado Y, Takahara S, Yamanishi K, Sonoda T & Takahashi M (1990) Effects of cyclosporine, azathioprine, mizoribine, and prednisolone on replication of human cytomegalovirus. Transplantation Proceedings 22:1682-1685.
80. Sidwell RW, Bailey KW, Wong MH, Barnard DL & Smee DF (2005) In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Research 68:10-17.
81. Sintchak MD & Nimmesgern E (2000) The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 47:163-184.
82. Smee DF, Bray M & Huggins JW (2001) Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antiviral Chemistry & Chemotherapy 12:327-335.
83. Snell NJC (2001) Ribavirin - current status of a broad spectrum antiviral agent. Expert Opinion on Pharmacotherapy 2:1317-1324.
84. Srivastava PC, Pickering MV, Allen LB, Streeter DG, Campbell MT, Witkowski JT, Sidwell RW & Robins RK (1977) Synthesis and antiviral activity of certain thiazole C-nucleosides. Journal of Medicinal Chemistry 20:256-262.
85. Srivastava PC & Robins RK (1983) Synthesis and antitumor activity of 2-β-D-ribofuranosylselenazole-4-carboxamide and related derivatives. Journal of Medicinal Chemistry 26:445-448.
86. Streeter DG & Koyama HHP (1976) Inhibition of purine nucleotide biosynthesis by 3-deazaguanine, its nucleoside and 5′-nucleotide. Biochemical Pharmacology 25:2413-2415.
87. Szekeres T, Sedlak J & Novotny L (2002) Benzamide riboside, a recent inhibitor of inosine 5′-monophosphate dehydrogenase induces transferrin receptors in cancer cells. Current Medicinal Chemistry 9:759-764.
88. Takhampunya R, Ubol S, Houng H-S, Cameron CE & Padmanabhan R (2006) Inhibition of dengue virus replication by mycophenolic acid and ribavirin. Journal of General Virology 87:1947-1952.
89. Wang W, Papov W, Minakawa N, Matsuda A, Biemann K & Hedstrom L (1996) Inactivation of inosine 5′-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide 5′-monophosphate. Biochemistry 35:95-101.
90. Yanagida K, Baba C & Baba M (2004) Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: synergistic effect of combination with interferon-α. Antiviral Research 64:195-201.
91. Ying C, Colonno R, De Clercq E & Neyts J (2007) Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir. Antiviral Research 73:192-196.